Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

Core Insights - Denali Therapeutics has received FDA accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm), marking the first FDA-approved biologic designed to cross the blood-brain barrier for treating Hunter syndrome in nearly 20 years [1][3][5] Company Overview - Denali Therapeutics is a biotechnology company focused on developing biotherapeutics that can effectively cross the blood-brain barrier using its proprietary TransportVehicle™ platform [27] - The company aims to transform treatment for neurodegenerative diseases and lysosomal storage disorders [27] Product Details - AVLAYAH is an enzyme replacement therapy indicated for pediatric patients with Hunter syndrome, specifically targeting neurologic manifestations [1][15] - The therapy demonstrated a 91% reduction in cerebrospinal fluid heparan sulfate levels by week 24 in a Phase 1/2 clinical trial, with 93% of treated patients achieving levels comparable to those without the disease [5][11] - AVLAYAH is administered once weekly and will soon be available in the U.S. [7] Clinical Development - The approval is based on a Phase 1/2 trial involving 47 participants, with ongoing studies (Phase 2/3 COMPASS) aimed at confirming clinical benefits and supporting global regulatory submissions [11][5] - The COMPASS study includes young adults with Hunter syndrome and is designed to provide further evidence of AVLAYAH's efficacy [11] Market Impact - The approval of AVLAYAH is seen as a significant advancement for the Hunter syndrome community, providing hope for families affected by this rare genetic disorder [6][12] - Denali has been awarded a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval, which can expedite future marketing applications [8] Community Response - The approval has been positively received by the MPS community, highlighting the collaboration between the FDA and advocacy groups to accelerate treatment development [2][6] - Families affected by Hunter syndrome express renewed optimism with the introduction of AVLAYAH, which addresses a critical unmet medical need [6][12]